BetaEntity Annotation Prototype

Entity family

Browse treatments

Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.

7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed

All extracted treatments

Showing 2,341–2,400 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.

Interferential therapy (IFT)1Intestinal transplant1Intestinal ultrasound1Intra-articular corticosteroid (IACS) injection1Intra-articular corticosteroid injections1Intracerebral dopamine cell transplants1Intralesional corticosteroid therapy1Intrapleural fibrinolytic treatment1Intrasaccular flow disruption1Intrathecal drug delivery1Intratympanic steroid therapy1Intravenous (IV) fluid therapy1Intravenous medicine administration1Intravenous potassium supplementation1Intravesical BCG instillations1Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy1Intravitreal therapies1Irreversible electroporation (IRE)1JAK inhibitors1Joint replacement1Jugular vein stenting1K-wire fixation1Ketamine-assisted psychotherapy1LAMS1LD-XRT1LDKTrelativeyearsgained1LDKTsurvival1LN induction treatment1LPA-targeted therapies1LRT1LTNIV1LV lead placement1LVAD implantation1LVR1Labor analgesia1Labour epidural analgesia1Laparoscopic surgery1Laparoscopy1Lateral femoral cutaneous nerve block1Left atrial ablation1Left ventricular assist devices1Level 1 disability management1Lipid Lowering TherapyPrescribed1Lipid-lowering therapies1Lokomat rehabilitation1Long term dopamine agonist therapy1Long-acting antiretroviral therapy1Long-acting injectable antiretroviral therapy1Low-dose ketamine infusion1Lumbar spine surgeries1Lymphatic Microsurgical Preventive Healing Approach1Lymphaticovenous anastomosis (LVA)1MATRix protocol1MB-TRAIL M28z CAR-T cell therapy1MBC regimen1MBE1MCMV peptide-epitope therapy1MDMA-assisted psychotherapy1MDT1MDT therapy programmes1

Articles mentioning treatments

7,227 articles · page 302 of 603
Conventional TherapyLuseogliflozinMAFLDMetabolic Associated Fatty Liver Disease (MAFLD)type 2 diabetes mellitus (T2DM)T2DM

…Biochemical and imaging outcomes at 3,6 monthsLuseogliflozin vs Conventional Therapy – Clinical Outcomes at 3 & 6 MonthsMean ± SD · Between-group P …

Flavonoid supplementationMetabolic dysfunction-associated steatotic liver disease (MASLD)PROSPEROMASLDNAFLDFlavonoidsEmbasePubMed

….47 kg/m2; 95% CI −1.50 to 0.56; p = 0.37; I2 = 0%).Conclusions Flavonoid supplementation may improve hepatocellular injury and insulin resistance in MAS…

endoscopic pancreatic interventionstirzepatidedulaglutidesemaglutidechronic pancreatitistype 2 diabetesChronic pancreatitis (CP)TriNetX US Collaborative Networkendoscopic pancreatic interventionsCP+1 more

…ng celiac plexus block (HR 0.51, 95% CI 0.34–0.78; p=0.001) and endoscopic pancreatic interventions (HR 0.48, 95% CI 0.41–0.56; p<0.001). Furthermore, the risk of …